Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Lamb

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Molecular Cancer Therapeutics|March 18, 2014
Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathwayPeiwen Yu, A Douglas Laird, Xiangnan Du, et al.
Molecular Cancer Therapeutics|February 1, 2015
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor ModelsPaul Foster, Kyoko Yamaguchi, Pin P Hsu, et al.
Journal of Medicinal Chemistry|April 14, 2012
Discovery and characterization of an inhibitor of glucosylceramide synthaseSteven Richards, Christopher J Larson, Elena S Koltun, et al.
Bioorganic & Medicinal Chemistry Letters|July 7, 2012
The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitorsMoon H Kim, Amy Lew Tsuhako, Erick W Co, et al.
Journal of Medicinal Chemistry|February 12, 2013
Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR)Craig S Takeuchi, Byung Gyu Kim, Charles M Blazey, et al.
Journal of Medicinal Chemistry|May 3, 2012
Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitorsJames W Leahy, Chris A Buhr, Henry W B Johnson, et al.
Clinical Obesity|December 14, 2024
An international Delphi consensus on patient preparation for metabolic and bariatric surgeryDanielle R Clyde, Reza Adib, Sarfaraz Baig, et al.
Obesity Surgery|November 11, 2025
Global Variations in Practices after Bariatric and Metabolic Surgery; the PARTNER StudyDanielle Clyde, Callum Grant, Juan Andres Aguiar Canales, et al.
BMJ Open|November 22, 2019
Laparoscopically assisted versus open oesophagectomy for patients with oesophageal cancer-the Randomised Oesophagectomy: Minimally Invasive or Open (ROMIO) study: protocol for a randomised controlled trial (RCT)Rachel C Brierley, Daisy Gaunt, Chris Metcalfe, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Molecular Cancer Therapeutics|March 18, 2014
Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathwayPeiwen Yu, A Douglas Laird, Xiangnan Du, et al.
Molecular Cancer Therapeutics|February 1, 2015
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor ModelsPaul Foster, Kyoko Yamaguchi, Pin P Hsu, et al.
Journal of Medicinal Chemistry|April 14, 2012
Discovery and characterization of an inhibitor of glucosylceramide synthaseSteven Richards, Christopher J Larson, Elena S Koltun, et al.
Bioorganic & Medicinal Chemistry Letters|July 7, 2012
The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitorsMoon H Kim, Amy Lew Tsuhako, Erick W Co, et al.
Journal of Medicinal Chemistry|February 12, 2013
Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR)Craig S Takeuchi, Byung Gyu Kim, Charles M Blazey, et al.
Journal of Medicinal Chemistry|May 3, 2012
Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitorsJames W Leahy, Chris A Buhr, Henry W B Johnson, et al.
Clinical Obesity|December 14, 2024
An international Delphi consensus on patient preparation for metabolic and bariatric surgeryDanielle R Clyde, Reza Adib, Sarfaraz Baig, et al.
Obesity Surgery|November 11, 2025
Global Variations in Practices after Bariatric and Metabolic Surgery; the PARTNER StudyDanielle Clyde, Callum Grant, Juan Andres Aguiar Canales, et al.
BMJ Open|November 22, 2019
Laparoscopically assisted versus open oesophagectomy for patients with oesophageal cancer-the Randomised Oesophagectomy: Minimally Invasive or Open (ROMIO) study: protocol for a randomised controlled trial (RCT)Rachel C Brierley, Daisy Gaunt, Chris Metcalfe, et al.
Pageof 5